Role of Positive Biopsy Core Ratio in Prostate Cancer Patients

Abstract

Background: The percentage of positive cores (PPC) is increasingly recognized as a prognostic factor in prostate cancer. However, the usefulness of PPC for patients undergoing androgen deprivation therapy (ADT) and high-risk group has not been adequately studied.Methods: A retrospective analysis was conducted of 255 patients who underwent prostate biopsy (allcase group). We examined the e cacy of PPC as a prognostic biomarker.Results: Eighty-nine patients were treated with ADT alone (ADT group), and 107 patients were classi ed as high-risk (high-risk group). The median duration of follow-up was 112.4 months, 85.3 months, and 110.0 months for the all-case group, ADT group, and high-risk group, respectively. Patients with PPC >60% had signi cantly shorter prostate cancer-speci c survival (CSS) and castration-resistant prostate cancerfree survival (CFS) in the all-case group and ADT group. In high-risk group, patients with PPC >60% had shorter CFS but no difference in CSS. Multivariate analysis showed that signi cant independent predictors of prostate CSS were the presence of metastasis at diagnosis and PPC >60% in the all-case group and ADT group.Conclusions: This study demonstrates that PPC may be a prognostic factor in ADT treatment and highrisk patients.

Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy

“…In the Japanese population, intermittent ADT has milder adverse events and a sufficiently better OS than continuous ADT, making it a valuable treatment of postoperative BCR [11]. In addition, it is important to select patients who will benefit from ADT by referring to new biomarkers that predict response to ADT, such as bone turnover markers and prostate cancer positive core rate [34,35].…”

Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer

“…It is initially responsive to androgen deprivation therapy (ADT) and eventually develops into castrationresistant PC (CRPC) in most cases and ultimately death [2]. A concerted effort has been made to explore new biomarkers to enhance diagnostic and prognostic strategies for PC [3,4]. Bone is a major visible metastatic site and is a potential invisible micrometastatic site in PC; thus, bone turnover markers have been reported as prognostic factors for PC and provide valuable information regarding the progression of bone metastasis and bone health under treatment of bone modifying agents, garnering considerable attention [5][6][7].…”